Top clinical issues of 2012
THE CLINICAL YEAR THAT WAS
EMOTIONAL debate and desperate politicking have surrounded the abortifacient mifepristone, or RU486, for decades but a milestone was reached this year when it was finally registered by the TGA.
After six years of restricted availability through the Authorised Prescriber Scheme, Mifepristone Linepharma and GyMiso (misoprostol) were freed up in August, becoming available to any prescriber trained by the sponsor, Marie Stopes International Australia (MSIA).
Earlier in the year Australia’s first death